Pfizer (NYSE:PFE) Trading Down 1.7% – Here’s Why

Pfizer Inc. (NYSE:PFE) dropped 1.7% during mid-day trading on Friday . The stock traded as low as $25.24 and last traded at $25.3090. Approximately 36,875,136 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 42,449,098 shares. The stock had previously closed at $25.75.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer continues to point to growth in recently launched and acquired drugs, with management saying new products and acquisitions drove a 22% revenue increase in that category during Q1. Strong demand for Nurtec and progress from the Seagen integration suggest the company’s non-COVID portfolio is gaining traction.
• Positive Sentiment: The company announced several clinical and development updates, including a Korea post-marketing study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, and a Japan RSV vaccine trial. These are incremental signs that Pfizer’s pipeline and international expansion efforts are still moving forward.
• Positive Sentiment: Pfizer also received a Europe label expansion for Hympavzi, which can broaden the therapy’s market opportunity and support future revenue growth.
• Neutral Sentiment: Coverage from analysts and market commentators has been mixed, with some calling Pfizer a defensive, cash-generating value name and others noting the stock’s lack of near-term earnings momentum. That keeps sentiment balanced rather than decisively bullish.
• Negative Sentiment: Recent commentary also highlighted that Pfizer’s stock slipped after its Q1 beat because investors remain concerned about falling COVID sales and looming patent cliffs. That overhang continues to limit enthusiasm despite operational progress.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. HSBC increased their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Barclays initiated coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective on the stock. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a research note on Thursday, February 12th. Royal Bank Of Canada restated an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.84.

Pfizer Trading Down 1.7%

The business’s fifty day simple moving average is $27.01 and its two-hundred day simple moving average is $26.19. The company has a market cap of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently made changes to their positions in PFE. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter worth about $1,830,986,000. Morgan Stanley grew its holdings in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after buying an additional 8,108,887 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after buying an additional 7,489,189 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.